BridgeBio highlights $1.7 billion cash position, targets three potential US launches by mid-2027

• BridgeBio presentation highlighted Attruby (acoramidis) launch momentum, citing Q2 2026 net product revenue of $222.4 million.
• Estimated Attruby share exceeded 25% of new-to-brand prescriptions, targeting 30%-40% peak share, peak market sales above $4 billion.
• Cash, cash equivalents, marketable securities totaled $1.7 billion as of June 30, 2026, positioned for three potential US launches by mid-2027.
• BBP-418 for LGMD2I/R9 carried a PDUFA date of Nov. 27, 2026; infigratinib for achondroplasia listed as NDA submitted.
• Encaleret for ADH1 carried a PDUFA date of May 8, 2027; Phase 3 work in chronic hypoparathyroidism was underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.